181 related articles for article (PubMed ID: 26926649)
1. Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.
Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2016 May; 60(5):2895-900. PubMed ID: 26926649
[TBL] [Abstract][Full Text] [Related]
2. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.
Ferro BE; Srivastava S; Deshpande D; Sherman CM; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1242-8. PubMed ID: 26643339
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.
Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2016 Jun; 60(6):3779-85. PubMed ID: 27067317
[TBL] [Abstract][Full Text] [Related]
4. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i30-i35. PubMed ID: 28922807
[TBL] [Abstract][Full Text] [Related]
5. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
6. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
7. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D
J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251
[TBL] [Abstract][Full Text] [Related]
8. Once-a-week tigecycline for the treatment of drug-resistant TB.
Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
[TBL] [Abstract][Full Text] [Related]
9. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.
Singh S; Wang JY; Heysell SK; McShane PJ; Wadle C; Shankar P; Huang HL; Pasipanodya J; Boorgula GD; Philley JV; Gumbo T; Srivastava S
Int J Antimicrob Agents; 2023 Jul; 62(1):106847. PubMed ID: 37187338
[TBL] [Abstract][Full Text] [Related]
10. Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.
Ruth MM; Sangen JJN; Pennings LJ; Schildkraut JA; Hoefsloot W; Magis-Escurra C; Wertheim HFL; van Ingen J
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104268
[No Abstract] [Full Text] [Related]
11. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
[TBL] [Abstract][Full Text] [Related]
12. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding.
Singh RSP; Mukker JK; Drescher SK; Deitchman AN; Derendorf H
Int J Antimicrob Agents; 2017 Apr; 49(4):449-455. PubMed ID: 28237830
[TBL] [Abstract][Full Text] [Related]
13. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
16. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
17. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
[TBL] [Abstract][Full Text] [Related]
18. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
Wei C; Ni W; Cai X; Cui J
Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
[TBL] [Abstract][Full Text] [Related]
19. Linezolid as treatment for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i24-i29. PubMed ID: 28922806
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
